Centre de Référence Maladies Rares


Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC)

FR: Biologie Fondamentale Appliquée à la Médecine

U1035Display navigation INSERM U1035 FR / EN

Christophe GROSSET

INSERM Research DirectorHead of MiRCaDe team,



Study the molecular processes, genes and microRNAs involved in liver cancer in adults (hepatocellular carcinoma) and children (hepatoblastoma).


1. Grosset, C, CY Chen, N Xu, N Sonenberg, H Jacquemin-Sablon, and AB Shyu, A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell, 2000. 103(1): p. 29-40.
2. Solanilla, A, C Grosset, C Lemercier, M Dupouy, FX Mahon, K Schweitzer, J Reiffers, B Weksler, and J Ripoche, Expression of Flt3-ligand by the endothelial cell. Leukemia, 2000. 14(1): p. 153-62.
3. Harizi, H, M Juzan, C Grosset, M Rashedi, and N Gualde, Dendritic cells issued in vitro from bone marrow produce PGE that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol, 2001. 209(1): p. 19-28.
4. Grosset, C, R Boniface, P Duchez, A Solanilla, B Cosson, and J Ripoche, In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element. J Biol Chem, 2004. 279(14): p. 13354-62.
5. Solanilla, A, JM Pasquet, JF Viallard, C Contin, C Grosset, J Dechanet-Merville, M Dupouy, M Landry, F Belloc, P Nurden, P Blanco, JF Moreau, JL Pellegrin, AT Nurden, and J Ripoche, Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005. 105(1): p. 215-8.
6. Sagliocco, F, B Laloo, B Cosson, L Laborde, M Castroviejo, J Rosenbaum, J Ripoche, and C Grosset, The ARE-associated factor AUF1 binds poly(A) in vitro in competition with PABP. Biochem J, 2006. 400(2): p. 337-47.
7. Laloo, B, D Simon, V Veillat, D Lauzel, V Guyonnet-Duperat, F Moreau-Gaudry, F Sagliocco, and C Grosset, Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method. Mol Cell Proteomics, 2009. 8(8): p. 1777-88.
8. Simon, D, B Laloo, M Barillot, T Barnetche, C Blanchard, C Rooryck, M Marche, I Burgelin, I Coupry, N Chassaing, B Gilbert-Dussardier, D Lacombe, C Grosset, and B Arveiler, A mutation in the 3’-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet, 2010. 19(10): p. 2015-27.
9. Jalvy-Delvaille, S., M. Maurel, V. Majo, N. Pierre, S. Chabas, C. Combe, J. Rosenbaum, F. Sagliocco, and C.F. Grosset, Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res, 2012. 40(3): p. 1356-65.
10. Maurel, M., S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet, F. Sagliocco, P. Bioulac-Sage, V. Pitard, H. Jacquemin-Sablon, J. Zucman-Rossi, B. Laloo, and C.F. Grosset, A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013. 57(1): p. 195-204.
11. Maurel, M., Dejeans, N., Taouji, S., Chevet, E. and C.F. Grosset. MicroRNA-1291-mediated silencing of IRE1alpha enhances Glypican-3 expression. RNA, 2013. 19, 778-788.
12. Indersie, E, S Lesjean, KB Hooks, F Sagliocco, T Ernault, S Cairo, M Merched-Sauvage, A Rullier, B Le Bail, S Taque, M Grotzer, S Branchereau, C Guettier, M Fabre, L Brugières, M Hagedorn, MA Buendia, and CF Grosset, MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling. Hepatology Communications, 2017. 1(2): p. 168-183.
13. Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Trezeguet V, Sagliocco F, Hagedorn M, Grosset CF. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget 2017;8(25):41211-26. doi: 10.18632/oncotarget.17162
14. Audoux, J, M Salson, CF Grosset, S Beaumeunier, JM Holder, T Commes, and N Philippe, SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines. BMC Bioinformatics, 2017. 18(1): p. 428.
15. Hooks, KB, J Audoux, H Fazli, S Lesjean, T Ernault, N Dugot-Senant, T Leste-Lasserre, M Hagedorn, B Rousseau, C Danet, S Branchereau, L Brugières, S Taque, C Guettier, M Fabre, A Rullier, MA Buendia, T Commes, AA Raymond*, and CF Grosset *, New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology, accepté pour publication, 2017. * co-last authors.
16. Saad, A, B Liet, G Joucla, X Santarelli, J Charpentier, S Claverol, CF Grosset, and V Trézéguet, Role of O-glycanation and convertase maturation of the soluble Glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry, in press, 2018.
17. Indersie, E, KB Hooks, C Capdevielle, M Fabre, N Dugot-Senant, A Desplat, S Lepreux, A Merched, CF Grosset, and M Hagedorn, Tracking cellular and molecular changes in a species-specific manner during experimental hepatoblastoma progression in vivo. Oncotarget, in press, 2018.

Subventions et contrats :

- INCa, TRANSLA 2013, “Regulation of Wnt/beta-catenin signaling and MicroRNAs: application to the treatment of hepatoblastoma, a rare pediatric cancer”, 3 years, (Applicant and coordinator: C.F. Grosset), Collaborators: Marie-Annick Buendia, U785 INSERM, Villejuif, France; Sophie Taque, Rennes University Hospital, France; Laurence Brugières, Gustave Roussy Institute, Villejuif, France; Stefano Cairo, Xentech company, France; SIOPEL network.
- FRM, BIOINFO 2013, “Functional genomic studies of hepatoblastoma by RNA-seq as a source of new diagnostic biomarkers and therapeutic targets”, 3 years, (Applicant and coordinator: C.F. Grosset), Collaborators: Marie-Annick Buendia, U785 INSERM, Villejuif, France; Thérèse Commes, U1040 INSERM, Montpellier, France.
- INCa, PLBIO 2012, “Glypican-3 : therapeutic target in liver cancer treatment”, 3 years, (Applicant and coordinator: C.F. Grosset), Collaborators: Véronique Trézéguet, Michel Hugues et Bernard Gallois, CBMN UMR 5248, Pessac, France; Jessica Zucman-Rossi, U674 INSERM, Paris, France; Jorge Filmus, Sunnybrook Health Sciences Centre, Toronto, Canada.
- ANR, 2010, “Pathophysiologic role of HDAC6 overexpression consecutive to a mutation abrogating a miRNA-mediated post-transcriptional regulation in an X-linked chondrodysplasia”, 3 years, (Applicant: B. Arveiler)
- Others grants : Cancéropôle Grand Sud-Ouest, La Ligue Nationale contre le Cancer, the University of Bordeaux Excellence Initiative 2014 and 2016 Post-doctoral fellowship program, charity grants (ESCAPE, Eva pour la Vie, Aidons Marina, KAena et les Lapinours, Fondation Flavien, Cassandra contre la leucémie, TFEM, Fondation Groupama pour la Santé), Région Aquitaine.
- Aquitaine Science Transfer/MATWIN coaching : Grant for a maturation project aiming at supporting the transfer of a microRNA to the clinic for the treatment of liver cancer.


  • Use of Glypican-3-targeting microRNAs for treating liver cancer. EP 15 3061072 European patent UNIVERSITE DE BORDEAUX-INSERM
  • Use of catenin-beta 1-targeting microRNAs for treating liver cancer. EP 15 3061130 European patent UNIVERSITE DE BORDEAUX-INSERM-UNIVERSITE PARIS SUD - PARIS XI


Back to organigramme

INSERM U1035 - University of Bordeaux
146 rue Léo Saignat - PE building south zone, 4th floor
33000 Bordeaux
Work +33 557 57 13 73/74